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Endometrial cancer, the most commonly diagnosed cancer of the female reproductive tract in 
developed countries, has a heritable component. To date, sixteen genetic risk regions have 
been robustly discovered by genome-wide association studies (GWAS) of endometrial 
cancer. Post-GWAS analyses including expression quantitative trait loci (eQTL) analysis and 
laboratory-based functional studies have been successful in identifying genes and pathways 
involved in endometrial carcinogenesis. Mendelian randomization analysis studies have 
confirmed factors causal for endometrial cancer risk, including increased body mass index 
and early onset of menarche. In this review, we summarize findings from GWAS and post-
GWAS analyses of endometrial cancer. We discuss clinical implications of these findings, 





Endometrial cancer, a malignancy of the lining of the uterus, is the most common 
gynaecological cancer diagnosed in developed countries, accounting for ~5% of all female 
cancers (http://gco.iarc.fr/today/home); age-standardized rates are steadily increasing (1). 
Endometrial carcinoma has traditionally been classified into two groups defined by 
histological subtype: endometrioid and non-endometrioid. Endometrioid endometrial cancers, 
which comprise the majority of endometrial cancers (80%), develop from glandular cells in 
the lining of endometrium and are generally associated with hyperplasia. These tumours are 
estrogen-dependent and tend to be low-grade with a favourable overall prognosis (2). 
Conversely, non-endometrioid endometrial cancers (commonly serous papillary or clear cell 
histology) are non-estrogen dependent and often exhibit a more aggressive clinical course 
that has a very poor prognosis (2).  
 
Endometrial cancer treatment has remained almost static over the last four decades relying 
principally on surgery, with full hysterectomy the most common and effective treatment for 
early stage disease (reviewed in 3).  However, the prognosis for advanced, recurrent or 
metastatic stage is still poor with high rates of recurrence and lower 3-year survival rates: 
endometrial cancer patients with local (vaginal) metastasis have a 3-year survival of 73%, 
pelvic metastasis 8% survival, and distant metastasis, 15% survival (4). Furthermore, the 
median survival time for advanced stage endometrial cancer is generally less than twelve 
months (5, 6).   
 
Women with a family history of endometrial cancer have an approximately 2-fold increased 
risk of developing the disease (7, 8). While some of the association between family history 
and endometrial cancer risk is attributable to shared environmental and/or lifestyle risk 
factors, twin studies have estimated the heritability to be between 27-52% (9-12).   
 
The currently known genetic architecture of endometrial cancer is displayed in Figure 1 and 
is consistent with a polygenic model of inheritance. Rare germline pathogenic (i.e. high-risk) 
variants in cancer syndrome genes, i.e. DNA mismatch repair genes associated with Lynch 
Syndrome (MLH1, MSH2, MSH6, and PMS2)  or PTEN in the context of Cowden’s disease  
explain ~3-5% of endometrial cancer cases at the population level (reviewed by 13).  
Evidence also supports the contribution of rare pathogenic variants in other DNA repair-
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related genes to endometrial cancer risk, including POLD1, POLE and possibly BRCA1 
(reviewed by 13). Pathogenic variants in other genes are likely to exist, but we would expect 
the frequency of such variants to be low, and thus they could account for only a small 
proportion of endometrial cancer cases. In contrast, although each endometrial cancer 
predisposition variant (such as the sixteen risk variants identified to date in genome-wide 
association studies (GWAS)(14-17)) has only a modest effect on risk, together they are likely 
to explain far more of the familial relative risk of the disease.  
 
This review will summarise the findings of recent endometrial cancer GWAS, and review 
post-GWAS analyses, including Mendelian randomization studies and the functional follow-
up of endometrial cancer genetic risk regions to identify candidate target genes.  
 
Genome-wide association studies of endometrial cancer risk 
 
Since the late 2000s, genotyping arrays, consisting of hundreds of thousands of common 
genetic variants across the genome, have revolutionized the study of the genetic basis of 
complex traits. For many diseases, GWAS have been remarkably successful in unlocking the 
biology of disease and driving therapeutic development (18); early indications suggest that 
this will also be true for endometrial cancer.  
 
In recent years, a series of GWAS in European populations have identified 16 endometrial 
cancer genetic risk regions (Table 1).  The first endometrial cancer GWAS, reported in 2011, 
identified a novel genetic risk region at 17q12, intronic to HNF1B (19). This study involved a 
stage 1 GWAS of 1,265 endometrioid endometrial cancer cases and 5,190 controls, followed 
by stage 2 validation of 47 genetic variants in 3,957 cases and 6,886 controls. This finding 
was directionally concordant in a subsequent GWAS by the Epidemiology of Endometrial 
Cancer Consortium (E2C2), including 4,989 cases across two stages (20). A meta-analysis of 
these two GWAS studies, with a third GWAS from the National Study of Endometrial 
Cancer Genetics, totalling 4,907 cases, identified a new, intergenic, risk region at 
chromosome 6p22.3 (14). 
 
The identification of additional endometrial cancer genetic risk regions has required 
collaboration and data sharing in order to achieve the sample sizes (and hence statistical 
power) required for the identification of variants with modest effect sizes. To this end, the 
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Endometrial Cancer Association Consortium (ECAC) was established to conduct large-scale 
meta-analyses of GWAS data. ECAC is an ongoing collaboration which currently includes 
twelve research groups, based in Europe, Australia and the USA, providing access to genetic 
and other information for more than 9,000 endometrial cancer cases of European ancestry.  
 
Around the time that ECAC was established, a custom genotyping array (“iCOGS”) was 
designed to test genetic associations with the risk of hormone-related cancers. The content of 
the iCOGS ~200K SNP genotyping array (21) is enriched for genetic variants with some 
prior evidence of association with one or more hormonal cancer, including variants selected 
on the basis of the first endometrial cancer GWAS. The genotyping of 4,402 ECAC cases on 
the iCOGS genotyping array, combined with previous GWAS data, led to the identification 
of five novel endometrial cancer risk regions (Table 1) (15) and allowed for fine-mapping 
studies of the known signals at HNF1B (16) and CYP19A1 (17) risk regions (the later had 
been previously identified in several candidate gene studies e.g. (22)).  
 
Recently, ECAC genotyped an additional 2,689 endometrial cancer cases using the 
OncoArray array (23). Along with data from the iCOGS projects, E2C2, the first release of 
the UK Biobank and a new GWAS conducted by the Women’s Health Initiative, this resulted 
in the largest endometrial cancer meta-GWAS to date (12,906 cases), enabling us to identify 
a further nine genetic regions associated with endometrial cancer risk (24). One previously 
identified region, near AKT1 on 14q32 (15), was not replicated by this analysis at a genome-
wide level of significance, bringing the total number of established genetic risk regions for 
endometrial cancer to sixteen.  
 
We have estimated that common genetic variants of the type that can be tagged by standard 
GWAS arrays potentially account for ~28% of the familial relative risk of endometrial cancer 
(24), and that the sixteen risk variants identified to date account for approximately one 
quarter of this figure, suggesting that many more genetic risk variants remain to be found. 
 
One limitation of the endometrial cancer GWAS conducted to date is that they have been 
almost exclusively restricted to European-ancestry populations. An early GWAS of 832 
Chinese endometrial cancer cases did not find any associations at the GWAS significance 
threshold, likely due to its small sample size and the necessity of using mostly European-
ancestry cases in the replication stages (25) because of a lack of genotyped East-Asian 
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ancestry cases. The expansion of adequately powered endometrial cancer GWAS to wider 
populations is therefore a priority, as indeed it is for all types of cancer, in order to identify 
the risk variants which are most relevant to women with different ethnic backgrounds (26). 
 
A second limitation is that the very small numbers of genotyped endometrial cancer cases 
with non-endometrioid histologies (e.g. only 434 of the 12,906 in the recent ECAC meta-
analysis were of serous/mixed-serous histology, the most common non-endometrioid 
histology) have precluded meaningful subtype-specific analyses of the type which have 
proved fruitful in the study of ovarian cancer susceptibility (27). While there is currently no 
evidence for a difference in genetic architecture between endometrial cancer subtypes, the 
limited data currently available for non-endometrioid histologies do not allow for well-
powered analyses of these subtypes. Thus, GWAS or sequencing studies using additional 
cases of rarer endometrial cancer subtypes are needed to increase statistical power, especially 
if subtypes can be analysed separately to provide cleaner histological phenotyping.   
 
Mendelian randomization studies of endometrial cancer risk factors 
 
Aside from genetic variants, numerous other factors have been reported as being associated 
with endometrial cancer risk, but observational studies alone are not always able to 
distinguish true, causal associations from artefactual associations caused by confounding or 
reverse causality. Mendelian randomization uses genetic variants known to be associated with 
a putative risk factor as ‘instruments’ in an instrumental variable analysis, thus testing the 
association of the risk factor in the absence of confounding (28, 29). The growing use of 
Mendelian randomization methods to examine risk factors for endometrial cancer (Table 2) 
has been facilitated by the success of GWAS in identifying the genetic variants associated 
with many of these proposed risk factors for endometrial cancer. 
 
Obesity is the strongest risk factor for endometrial cancer, with observational studies 
observing up to eight-fold increased risk between obese women (body mass index; BMI ≥ 40 
kg/m2) compared with lean women (BMI < 25 kg/m2). Mendelian randomization analysis 
has confirmed this relationship, finding strong evidence for a relationship between obesity, as 
measured by BMI, but not as measured by waist-hip ratio, and endometrial cancer risk (30). 
An earlier Mendelian randomization study of diabetic-related traits found a significant 
relationship between increased insulin levels and endometrial cancer risk (31), but did not 
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find type 2 diabetes or glucose levels to be associated with endometrial cancer, suggesting 
that observed associations between type 2 diabetes and endometrial cancer may be 
consequences of residual confounding (31).  
 
Excessive endogenous and exogenous estrogen exposure, unopposed by progesterone, is a 
well-established risk factor for the development and progression of endometrial cancer (32). 
A Mendelian randomization analysis using the genetic variant most strongly associated with 
serum estradiol levels in postmenopausal women verified the relationship between 
postmenopausal estrogen levels and endometrial cancer (17). Further, each year of delay in 
menarche (which would be expected to reduce lifetime estrogen exposure), has been 
confirmed by Mendelian randomization as producing a ~12% reduction in endometrial cancer 
risk, even after adjusting for the effects of genetically-predicted BMI (24, 33).  
 
The status of other hypothesized risk factors for endometrial cancer, including polycystic 
ovary syndrome (PCOS), endometriosis and uterine fibroids, remain unclear. The 
epidemiological associations reported for these risk factors (or lack thereof) may be 
confounded by co-existing conditions (e.g. PCOS with infertility/anovulation) or 
measurement limitations (e.g. under- and mis-diagnosis of endometriosis). Future Mendelian 
randomization studies to investigate these epidemiological risk factors, in conjunction with 
results from observational studies, will provide important information that can be used 
clinically to identify women at risk of endometrial cancer, and to inform prevention 
strategies.    
 
Pleiotropy and cross-disease GWAS studies 
 
One of the conclusions that can be drawn from the ever-growing catalogue of complex-trait 
GWAS results is that pleiotropy is very widespread (reviewed by 18). Endometrial cancer is 
no exception to this pattern; from the sixteen endometrial cancer genetic risk regions 
identified to date, fourteen are coincident with risk regions for other cancers (within 1Mb), 
twelve regions are associated with anthropometric traits, one region with endometriosis and 
six with traits associated with steroid hormone levels (as at May 2018; Table 1). While 
individual risk variants at these regions are not commonly shared between endometrial cancer 
and these traits, it is anticipated that the different trait-associated variants regulate the same 




Some of the pleiotropy observed with endometrial cancer has been supported by LD Score 
regression analyses (34). Endometrial cancer GWAS summary statistics and GWAS data 
publicly available for 224 non-cancer traits have found several BMI-related traits to be 
significantly genetically correlated with endometrial cancer risk (24). A similar study 
performed using endometriosis GWAS summary statistics revealed a significant correlation 
between this disease and endometrial cancer risk (rg = 0.23; P=9.3×10
-3
)(35). LD Score 
regression analyses between endometrial cancer and other cancer types are in progress, and 
will likely yield intriguing results. 
 
Given the widespread pleiotropy observed across the genome, it is not surprising that 
pleiotropic cross-disease GWAS meta-analysis has been used successfully to increase power 
and identify regions relevant to multiple diseases (36-38). A cross-cancer GWAS study of 
endometrial cancer with colorectal cancer identified a risk region at 12q24.12, where the 
most significant association is with a missense variant located in the SH2B3 gene (39). 
Subsequent analyses in larger cohorts have found this variant to be independently associated 
with the risk of both of these cancers (24, 40). Future large-scale cross-cancer GWAS meta-
analyses are planned to identify genetic risk regions important for carcinogenesis across 
multiple tissues. Cross-disease meta-analysis of GWAS data from endometrial cancer and 
endometriosis identified a risk region relevant to both diseases at 9p23 within the PTPRD 
gene (35). Further, a sub-genome-wide significant region in this cross-disease analysis (35) 
(12p12.1 locus rs2278868 P = 5.5×10-6) was subsequently identified as a risk region for 
endometrial cancer in a larger cohort (24). Meta-analyses of GWAS data from other relevant 
traits or diseases (e.g. uterine fibroids) could also provide insights into pathways relevant for 
endometrial cancer aetiology. 
 
Enrichment of endometrial cancer risk variants in functional elements 
 
The correlation structure of common genetic variants means that the genetic variant with the 
most statistically significant association with disease at a particular locus in a GWAS is not 
necessarily causally associated with the disease – the apparent association may well be driven 
by a different causal variant(s) correlated through linkage disequilibrium. It is therefore 
conventional to think of the most significant variant at a locus as merely the ‘lead’ or ‘index’ 
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variant for a wider set of correlated variants, any of which is a credible causal variant. 
Definitions vary, but these sets of credible causal variants are usually delineated according to 
the extent of the linkage disequilibrium with the lead variant, and the difference between the 
level of statistical significance of the lead variant and that of the candidate variants (41).  
 
Of the credible causal variants identified from the endometrial cancer GWAS risk studies, 
only three identified to date are exonic. This observation is consistent with the distributions 
of the GWAS-identified variants for most other complex diseases (reviewed by 18). The sets 
of credible causal risk variants identified in GWASs of other diseases are enriched for 
localisation to active epigenetic marks, characteristic of regulatory elements, mapped from 
trait-relevant cells or tissues (42, 43). Correspondingly, credible causal variants from the 
most recently identified nine endometrial cancer genetic risk regions demonstrated a greater 
enrichment in active epigenetic marks from endometrial cancer cell lines and tissues, 
compared to credible causal variants for related (i.e. endometriosis) or unrelated (i.e. 
schizophrenia) diseases (24). Also, significantly more credible causal endometrial cancer risk 
variants localised to active epigenetic marks from estrogen-stimulated endometrial cancer 
cells in comparison to such marks from unstimulated cells (24). These findings thus support 
the use of these epigenetic marks in identifying functional (i.e. likely causal) variants at 
endometrial cancer risk regions and further highlight the role of estrogen in endometrial 
cancer development. 
 
Functional follow-up studies of endometrial cancer risk GWAS 
 
The identification of the target genes that mediate the effects of GWAS variants is an 
important step for clinical translation of findings e.g. the identification of opportunities for 
drug repositioning (44). Experimental and/or bioinformatic studies are required for target 
gene identification but are very often neglected (45). Several such functional studies have 
been performed to date for endometrial cancer risk GWAS and are discussed below. 
 
The approaches taken in functional follow-up studies of GWAS are, in part, determined by 
the locations of the credible causal variants. For example, at the 17q12 endometrial cancer 
risk region, three candidate causal variants are located in an extended region of the HNF1B 
promoter and so reporter gene assays were performed to assess effects on promoter activity 
(16). In endometrial cancer cells, the risk alleles of two of the 17q12 credible causal variants 
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were associated with enhanced HNF1B promoter activity, and the effect of one of these 
variants (rs11263763) was supported by an association between the risk allele of rs11263763 
and increased HNF1B expression in endometrial tumours (16). It is intriguing to note that 
rare HNF1B variants, reported to abrogate HNF1B expression, reduce secretion of insulin 
which Mendelian randomisation has shown to be an endometrial cancer risk factor (31). This 
finding is consistent with the upregulation of HNF1B promoter activity and transcription by 
the risk allele of rs11263763, potentially providing a mechanism for the effect of the 
endometrial cancer risk variation at this region through increased insulin secretion.  
 
Due to haplotype structure, GWAS association signals often map to large genomic intervals, 
owing to extensive linkage disequilibrium (LD) between common variants, making 
identification of likely causal variants and their target genes extremely challenging. 
Moreover, it is not obvious which genes may be targeted for regulation; especially as 
functional elements such as enhancers can regulate genes through long-range chromatin 
looping interactions, up to two megabases away (reviewed in 46); Figure 2). Indeed, in 
general, GWAS variants regulate the nearest gene only one third of the time (47, 48) and 
likely target multiple genes through long-range chromatin looping (49). To address these 
issues, bioinformatic approaches that use correlations between gene expression and 
epigenomic features to identify enhancers and their corresponding target genes have been 
applied to endometrial cancer risk loci and revealed a number of candidate target genes 
(Table 1) (15). However, these candidate target genes still require validation by other means, 
as described below. 
 
Long-range chromatin looping can be assessed experimentally to identify genes that may be 
targeted by credible causal variants through regulatory features such as enhancers. These 
approaches centre on the chromatin conformation capture (3C) technique which identifies 
interacting genomic regions (reviewed in 50). A 3C method was used at three endometrial 
cancer risk loci to identify looping between regions containing credible causal variants and 
the promoters of MYC (8q24.21 risk locus (51)), KLF5 (13q22.1 risk locus (15)), and AKT1 
and ZBTB42 (the non-replicated 14q32 risk locus (52)). Notably, the interactions between 





Looping interactions alone do not provide evidence of gene regulation. Therefore, reporter 
gene assays in endometrial cancer cells have been used to assess the effects of looping 
credible causal variants on promoter activity at endometrial cancer risk loci. The risk allele of 
a looping variant (rs9600103) at the 13q22.1 risk locus increased the activity of a minimal 
promoter (15). At the 14q32 risk locus, an allele of a looping variant (rs2494737) enhanced 
the activity of a canonical and alternative promoter of AKT1, but had no effect on ZBTB42 
promoter activity (52). No study has yet looked at the effect of looping candidate causal risk 
variants on MYC promoter activity at the 8q24 risk region. 
 
Evidence from expression quantitative trait loci (eQTL) analyses has demonstrated that 
GWAS variants are enriched for variants that associate with gene expression (53, 54), 
indicating that these variants likely affect gene regulation and providing an approach to 
identify target genes at GWAS loci (54, 55). In the most recent endometrial cancer risk 
GWAS (24), eQTL analyses were performed using data from a variety of tissue sources to 
identify genes whose expression associated with risk variants from the newly identified loci 
(Table 1). Several of the identified eQTL genes were either tumour suppressors (NF1 (56)), 
negative regulators of oncoproteins (SH2B3 (57)) or oncogenes (CDCA8 (58) and WT1-AS 
(59)). Consistent with these functions, risk alleles were associated with decreased expression 
of NF1 and SH2B3 and increased expression of CDCA8 and WT1-AS (24). 
 
Network analysis of candidate target genes of endometrial cancer risk variants 
 
Analysis of the 25 candidate target genes identified to date (Table 4) has revealed a network 
which contains 18 of these genes (24). Major network hubs were either known oncoproteins 
or tumour suppressors, including the protein encoded by the candidate target gene MYC and 
proteins encoded by genes that are somatically mutated in endometrial cancer (CCND1, 
CTNNB1 and TP53 (60)). An enrichment of these and other network genes was observed in 
corresponding pathways such as cyclins and cell cycle regulation, Wnt/-catenin and P53 
signalling. Interestingly, given the role of obesity in increasing endometrial cancer risk, there 
was also an enrichment of network genes in an adipogenesis pathway. As further candidate 
target genes are identified, this network will likely be refined and additional networks 
revealed. Furthermore, network genes may point to additional endometrial cancer genetic risk 





Future functional follow-up approaches for endometrial cancer risk GWAS 
 
Although candidate target genes have been identified at 11 of the 17 risk regions (Table 1), it 
is clear that other approaches are needed to identify further candidate target genes. The 
transcriptome-wide association study method (47) enables gene expression to be predicted in 
endometrial cancer GWAS datasets (from existing studies of tissue with genotype and gene 
expression data e.g. the Genotype Tissue Expression project (61) and The Cancer Genome 
Atlas (62), thus allowing the testing of associations between imputed gene expression and 
endometrial cancer risk. Additionally, a number of global 3C techniques are now available 
(50)) to systematically assess chromatin interactions across the entire genome, rather than 
being restricted to single loci, and could be used to assess all endometrial cancer genetic risk 
regions for candidate target genes. However, these approaches still do not provide definitive 
evidence that credible casual variants directly affect gene expression and require additional 
studies to determine variant function. The final steps to validate the functionality of credible 
causal variants and their target genes and determine their effects on cellular phenotypes will 
require systems such as CRISPR/Cas9 which could be used to generate isogenic cell lines 
that differ by the alleles of credible causal variants (reviewed in 63) or activate/inactivate 
chromatin encompassing these variants  (reviewed in 64). 
 
Conclusions and Future Directions 
 
Plans by ECAC to conduct a significantly expanded meta-GWAS, including imputation to 
more dense reference panels, are likely to yield additional endometrial cancer risk loci. 
Sample sizes will also be increased by conducting cross-disease meta-analysis studies of 
endometrial cancer and related diseases: an additional benefit of such studies is the potential 
to identify novel pleiotropic risk loci, and hence insights into shared underlying biology. 
Looking further ahead, large-scale sequencing initiatives are required for the identification of 
rarer variants (i.e. not tagged by standard GWAS-type arrays) associated with modest to high 
risks of endometrial cancer.  
 
The next phase of research will be to progress identified endometrial cancer risk variants to 
translational and clinical outcomes for patients. Results from Mendelian randomisation 
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analyses determining causality of epidemiological risk facts have potential to identify at-risk 
women for altered screening management. Another avenue for clinical translation will be the 
development of polygenic risk scores for endometrial cancer. Application of this approach in 
BRCA1/2 pathogenic variant carriers is able to predict which individuals are most likely to 
develop breast or ovarian cancer (65). Similarly, a polygenic risk score could be developed to 
predict which women from Lynch Syndrome families are most likely to be diagnosed with 
endometrial cancer, and who would derive the most benefit from increased screening and/or 
risk-reducing steps. The development of polygenic risk scores reinforces the importance of 
performing GWAS in non-European populations. Given the differences in allele frequencies, 
effect sizes and LD patterns across ethnic groups, polygenic risk scores developed using 
primarily European sample sets may not be translatable to other populations. Therefore 
expansion of endometrial cancer GWAS to non-European populations is an essential research 
priority so that comparable polygenic risk scores will be available for all ethnic groups.   
 
A key ongoing challenge is the identification of the causal genes that mediate the effects of 
endometrial cancer risk variants. Although post-GWAS studies of endometrial cancer risk 
have identified candidate target genes at individual risk regions, endometrial cancer 
functional genomic data needs to be generated in order to systematically assess all risk 
regions. Furthermore, it has not yet been experimentally shown that the regulation of 
candidate target genes contributes to endometrial cancer risk through effects on cellular 
phenotypes. Importantly, such experimental studies are necessary to spur the development of 
new therapies through the identification of new drug targets, or targets for which drugs 
already exist. Indeed, the use of a drug target with a genetic basis appears to improve the 
likelihood of successful drug development (66), highlighting the inherent potential for 
clinical translation from studies identifying the likely causal genes underlying endometrial 
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Table 1. Genetic risk regions and candidate target genes identified by endometrial cancer genetic association studies to date.  
Risk 
locus 
Other relevant traits identified by GWAS at this locus* Candidate 
target/Closest 
gene† 
Evidence for targeting Involvement in relevant 




1p34.3 Cancer: ovarian CDCA8 eQTL (24) - (24) 
2p16.1 Cancer: Hodgkin’s lymphoma BCL11A - - (24) 
6q22.3 Cancer: melanoma, neuroblastoma 
Anthropometric: height, body mass index 
Steroid hormone-related: bone mineral density 
SOX4, CASC15 - - (14, 24) 
6q22.31 Cancer: bladder 
Anthropometric: height, hip circumference 
Steroid hormone-related: Age of menarche 
HEY2 Bioinformatic prediction (15) Notch signalling (14, 15, 24) 
 NCOA7 Bioinformatic prediction (15) Endometrial cancer signalling  
8q24.21 Cancer: acute lymphoblastic leukemia, breast, diffuse large B cell lymphoma, follicular 
lymphoma, glioma, Hodgkin’s lymphoma, ovarian, pancreatic 
Anthropometric: height 
MIR1204 Bioinformatic prediction (15) - (15, 24) 
 MIR1205 Bioinformatic prediction (15) -  
 MIR1207 Bioinformatic prediction (15) -  
 MIR1208 Bioinformatic prediction (15) -  
 MYC Chromatin looping; bioinformatic prediction 
(15) 
Molecular mechanisms of cancer 
Wnt/-catenin signalling 
Estrogen-mediated S-phase entry 
G1/S checkpoint regulation 
 
9p21.3 Cancer: acute lymphoblastic leukemia, breast, chronic lymphocytic leukemia, glioma, 
glioblastoma, lung, melanoma, multiple myeloma, nasophayngeal, oral cavity, prostate 
Anthropometric: body mass index 
Endometriosis 
CDKN2A/B - - (24) 
11p13 Anthropometric: body mass index, waist-hip ratio CCDC73 eQTL (24) - (24) 
 EIF3M eQTL (24) EIF2 signalling  
 RCN1 eQTL (24) -  
 TCP11L1 eQTL (24) -  
 WT1-AS eQTL (24) -  
12p12.1 Cancer: esophageal, renal cell 
Anthropometric: waist-hip ratio 
SSPN - - (24) 
12q24.12 Cancer: breast, colorectal, esophageal 
Anthropometric: body mass index  
SH2B3 eQTL (24) - (24) 
12q24.21 Cancer: esophageal, laryngeal squamous cell, pancreatic, prostate 
Steroid hormone-related: mammographic density 
SNORA27 - - (24) 
13q22.1 Cancer: breast, chronic lymphocytic leukemia, pancreatic, prostate 
Steroid hormone-related: age of menarche  
KLF5 Functional analyses; bioinformatic prediction 
(15) 
Adipogenesis pathway (14, 15, 24) 
15q15.1 Cancer: Ewing sarcoma 
Anthropometric: body mass index, height 
Steroid hormone-related: age of menopause 
BMF Bioinformatic prediction (15) - (15, 24) 
 GPR176 Bioinformatic prediction (15) -  
 SRP14-AS1 Bioinformatic prediction (15) -  
 SRP14 Bioinformatic prediction (15) -  
15q21.2 Anthropometric: body mass index, height 
Steroid hormone-related: bone mineral density,  estradiol levels, follicle stimulating 
hormone  
CYP19A1 eQTL and association with estradiol levels (17) Estrogen-dependent breast cancer 
signalling 
(15, 17, 24) 
17q11.2 Cancer: breast, prostate 
Anthropometric: body mass index, height, hip circumference, waist circumference 
EVI2A eQTL (24) - (24) 
 NF1 eQTL (24) Molecular mechanisms of cancer  
 SUZ12 eQTL (24) -  
17q12 Cancer: ovarian, pancreatic, prostate, testicular germ cell 
Anthropometric: body mass index, height 
HNF1B Functional analyses; eQTL (16) Pigment epithelium-derived factor 
(PEDF) signaling 
(14-16, 19, 24) 
17q21.32 Cancer: ovarian 
Anthropometric: body fat percentage, body mass index, height, obesity 
SNX11 eQTL (24) - (24) 
*From GWAS catalog (https://www.ebi.ac.uk/gwas/home), accessed May 2018 †Bolded genes have evidence for being a candidate target gene, unbolded genes are closest genes 
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Table 2. Mendelian randomisation studies assessing the causal relationship between putative risk factors and endometrial cancer risk. 
Trait assessed  





Association results Comments Reference 
Type 2 Diabetes 
(49 variants) 
1,287 8,273 0.91 (0.79-1.04); P=0.16 Endometrioid endometrial cancer cases only (31) 
Increased fasting glucose 
(36 variants) 
1,287 8,273 1.00 (0.67-1.50); P=0.99 Endometrioid endometrial cancer cases only (31) 
Increased fasting insulin 
(18 variants) 
1,287 8,273 2.34 (1.06-5.14); P=0.03 Endometrioid endometrial cancer cases only (31) 
Early insulin secretion 
(17 variants) 
1,287 8,273 1.40 (1.12-1.76); P=0.003 Endometrioid endometrial cancer cases only (31) 
Body mass index 
(32 variants) 
1,287 8,273 3.86 (2.24-6.64); P=1×10-6 Endometrioid endometrial cancer cases only (31) 
Body mass index 
(97 variants) 
3,376 3,867 1.13 (1.04-1.22); P=0.002 
Endometrioid endometrial cancer cases only. Association did not 
persist after adjustment for measured body mass index. 
(67) 
Body mass index 
(77 variants) 
6,609 37,926 2.011 (1.94-2.28); P=3.4×10-17 
All endometrial cancer cases. Remained significant after 




6,609 37,926 1.02 (0.99-1.04); P=0.09 
All endometrial cancer cases. Waist-hip ratio variants are those 




6,609 37,926 0.97 (0.63-1.31); P=0.86 
All endometrial cancer cases. Waist-hip ratio variants are those 
that were associated with this trait in men and women. 
(30) 
Serum estradiol level 
(1 variant) 
6,608 37,925 1.15 (1.11-1.21); 4.8×10-11 
All endometrial cancer cases. CYP19A1 variant rs727478 used to 
predict serum estradiol level (10% increase per A-allele). 
(17) 
Menarche (age of onset) 
(237 variants) 
6,609 37,926 0.78 (0.70-0.87); P=1.0×10-5 
All endometrial cancer cases. Menarche variants were adjusted for 












Figure 1. Schematic of the known genetic architecture of endometrial cancer. Low frequency 
genetic variants from PTEN and the mismatch repair genes (MLH1, MSH2, MSH6 and 
PMS2) are considered high risk variants (estimated risk >4-fold). Common variants 
(frequency > 1%) identified by GWAS are considered low risk variants (estimated risk <2-
fold). No variants associated with moderate risk (estimated risk ~2 to 4-fold) are currently 
established. Although variants in other genes have been implicated in predisposition to 
endometrial cancer, including STK11, POLD and POLE, their clinical utility for the purpose 
of altering patient management is unclear, since risk estimates are imprecise, and/or based on 
a limited number of studies with potential for ascertainment bias (13).  
 
Figure 2. Long-range gene regulation via chromatin looping events and functional 
consequences of genetic variants in epigenomic features. Panel A depicts chromatin looping 
bringing an enhancer (characterised by active histone marks) into proximity with a gene 
promoter, allowing transcription factor (TF) binding and gene transcription. Panel B depicts 
the same scenario with a variant allele (A to G change), resulting in further TF binding and 
increased gene expression. 
 
 


